Apotex Sevmia challenges Wegovy as generic GLP-1 competition begins in Canada
Read how Apotex’s Sevmia approval could reshape Canada’s semaglutide market, and why dosing, pricing and reimbursement still matter.
Pharma & Biotech
Pharma & Biotech
Can Sciwind Biosciences’ ecnoglutide challenge conventional GLP-1 drugs in the expanding obesity market?
China approves Sciwind Biosciences’ ecnoglutide for weight management. Discover what the biased GLP-1 mechanism could change in the obesity drug race.
Pharma & Biotech
Can higher-dose Wegovy reshape the obesity treatment curve for Novo Nordisk?
Novo Nordisk’s semaglutide 7.2 mg dose aims to raise Wegovy’s weight loss impact. Learn how this could shift obesity treatment and reshape clinical norms.